Anixa Biosciences Q1 2026 Financial Results: Key Insights for Investors

Overview

Anixa Biosciences, Inc. has released its unaudited financial results for the first quarter ended January 31, 2026. The company continues to be listed on the NASDAQ Capital Market under the symbol “ANIX.” The quarterly report is filed under Form 10-Q, providing a comprehensive overview of the company’s financial condition, results of operations, and key developments for investors.

Key Financial Highlights

• Net Loss: Anixa reported a net loss of \$2.6 million for the three months ended January 31, 2026, compared to a net loss of \$3.2 million for the same period in 2025. This represents a reduction in quarterly net loss year-over-year, which may indicate improving expense control or other operational efficiencies.
• Revenues: As typical for a clinical-stage biosciences company, the financials do not reflect significant operating revenues.
• Shareholders’ Equity: As of January 31, 2026, total shareholders’ equity was \$15.1 million, slightly down from \$15.2 million as of October 31, 2025.
• Cash Position: The company reported a net increase in cash and cash equivalents during the quarter, supported by proceeds from an at-the-market (ATM) offering and the exercise of stock options.
• Stock Issuance and Funding:
  • \$1.6 million was raised through an at-the-market offering during the quarter.
  • An additional \$60,000 was raised from the exercise of stock options.
  • Share-based compensation expenses for the quarter totaled \$768,000 for employees and directors, and \$28,000 for consultants.
• Common Stock Outstanding: As of January 31, 2026, the weighted average number of common shares outstanding was approximately 33.1 million (basic and diluted).
• Earnings Per Share (EPS): Basic and diluted net loss per share was (\$0.08), compared to (\$0.10) for the prior year’s quarter.
• Short-Term Investments: The company generated \$13.8 million of proceeds from sales of short-term investments during the quarter.

Balance Sheet and Capital Structure

• No Preferred Stock Outstanding: As of January 31, 2026, the company had no preferred stock issued or outstanding, including no shares of Series A convertible preferred stock.
• Noncontrolling Interest: The noncontrolling interest component of equity was (\$1.2 million) as of January 31, 2026.
• Total Liabilities and Equity: amounted to \$15.2 million at the end of the quarter.

Market Status and Compliance

• The company’s common stock continues to be registered and traded on the NASDAQ Capital Market under the ticker “ANIX.”
• Anixa is classified as a non-accelerated filer and a smaller reporting company under SEC rules.
• The company is not an emerging growth company and has indicated that it is not a shell company.

Potential Price-Sensitive Information for Shareholders

• Capital Raise via ATM Offering: The company’s ability to raise \$1.6 million during the quarter through an at-the-market offering is significant, as it strengthens the balance sheet and provides additional resources to fund operations and R&D. The ability to access capital markets is a positive signal for investors, especially in a challenging macro environment.
• Reduction in Net Loss: The narrowing of the net loss compared to the prior year could indicate improving operational efficiency or cost controls, which is generally viewed positively by investors.
• No Preferred Stock Dilution: The absence of preferred stock, especially convertible preferreds, means common shareholders are not at risk of dilution from conversion or preferred dividend overhangs.
• Ongoing Share-Based Compensation: The company continues to use stock options as a significant part of compensation, which could result in future dilution.

Summary Table

Conclusion

Anixa Biosciences displays prudent cash and equity management, with its capital raise efforts and cost controls leading to a smaller net loss for the quarter. The company remains committed to funding its ongoing operations and research efforts. The improved bottom line and successful capital raise could potentially be viewed as positive signals by the market, although the company remains in a pre-revenue phase.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full financial statements and consult with their financial advisors before making any investment decisions regarding Anixa Biosciences, Inc. Past performance is not indicative of future results, and all investments carry risk.

View Anixa Biosciences Inc Historical chart here